Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.46 USD
+0.03 (2.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.47 +0.01 (0.68%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SPRO 1.46 +0.03(2.10%)
Will SPRO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SPRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRO
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
SPRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?
What's in Store for Boston Scientific (BSX) in Q3 Earnings?
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
Other News for SPRO
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Spero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
Spero Therapeutics files $300M mixed securities shelf
Spero Therapeutics files $300M mixed securities shelf
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session